Kenvue Inc. (NYSE:KVUE) Shares Bought by Savant Capital LLC

Savant Capital LLC boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 5.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,241 shares of the company’s stock after buying an additional 798 shares during the period. Savant Capital LLC’s holdings in Kenvue were worth $347,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the company. State Street Corp raised its holdings in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Kenvue by 8.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock worth $2,011,832,000 after acquiring an additional 7,115,374 shares during the last quarter. Holocene Advisors LP increased its stake in Kenvue by 75.5% during the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock worth $321,194,000 after acquiring an additional 5,975,392 shares during the last quarter. M&G PLC grew its stake in shares of Kenvue by 538.0% in the third quarter. M&G PLC now owns 4,341,172 shares of the company’s stock valued at $99,847,000 after buying an additional 3,660,730 shares in the last quarter. Finally, FMR LLC grew its stake in shares of Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after buying an additional 3,075,019 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $21.94 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm’s 50-day moving average price is $21.30 and its two-hundred day moving average price is $22.12. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The stock has a market capitalization of $42.07 billion, a P/E ratio of 41.40, a P/E/G ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.74%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

Analyst Ratings Changes

A number of brokerages have issued reports on KVUE. UBS Group decreased their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Barclays reduced their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Canaccord Genuity Group cut their target price on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.